Investor Relations

AgeneBio is dedicated to developing the first and only treatments designed to address hippocampal overactivity.

Investment Thesis

Novel Pipeline for Neurological and Psychiatric Diseases Addressing Significant Unmet Medical Needs

  • Extensive Phase 3 expertise in Alzheimer’s disease (AD) among R&D leadership team
  • Science recognized as novel and promising by AD experts
  • Phase 3 program poised for immediate initiation
  • Favorable risk/benefit profile for high unmet need disease state
  • Multi-billion dollar revenue potential with lifecycle opportunities

Investor Materials

AgeneBio Corporate Presentation August ’17


AgeneBio to Speak at ASENT 2018 Annual Meeting

AgeneBio Founder Michela Gallagher to Speak at 2018 NIH Alzheimer’s Research Summit

AgeneBio Receives NIH Grant to Initiate Phase 3 HOPE4MCI Trial to Treat MCI Due to Alzheimer’s Disease

 

 

More news releases

AgeneBio in the news


Email Alerts

Sign up for email alerts here.


Investor Contact

Jerry McLaughlin
President and CEO
investorrelations@agenebio.com

Media Contact

Jennifer Guinan
Sage Strategic Marketing
Jennifer@sagestrat.com
610.410.8111